3-hydroxy-4-(4-hydroxyphenyl)-1H-pyrrole-2,5-dione | 264224-11-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-hydroxy-4-(4-hydroxyphenyl)-1H-pyrrole-2,5-dione
• 英文别名: 3-hydroxy-4-(4-hydroxyphenyl)pyrrole-2,5-dione
• CAS: 264224-11-5
• 化学式: C₁₀H₇NO₄
• 分子量: 205.17
• InChiKey: RUCSHJJEGZMYME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-hydroxy-4-(4-hydroxyphenyl)-1H-pyrrole-2,5-dione 在 草酰氯 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-(4-hydroxyphenyl)-4-(2-methylindolin-1-yl)-1H-pyrrole-2,5-dione
  参考文献：
  名称：

  Targeting multidrug resistant Staphylococcus infections with bacterial histidine kinase inhibitors

  摘要：

  我们报告了一种针对耐甲氧西林金黄色葡萄球菌（MRSA）的抗病毒策略。在小鼠模型中，最有效的先导物使 MRSA 皮肤感染引起的病变面积缩小了 65%。

  DOI：

  10.1039/d2sc05369a
• 作为产物：
  描述：

  2-氧代戊酸乙酯 、 4-羟基苯乙酰胺 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 生成 3-hydroxy-4-(4-hydroxyphenyl)-1H-pyrrole-2,5-dione
  参考文献：
  名称：

  Targeting multidrug resistant Staphylococcus infections with bacterial histidine kinase inhibitors

  摘要：

  我们报告了一种针对耐甲氧西林金黄色葡萄球菌（MRSA）的抗病毒策略。在小鼠模型中，最有效的先导物使 MRSA 皮肤感染引起的病变面积缩小了 65%。

  DOI：

  10.1039/d2sc05369a

文献信息

• Novel method and compounds
  申请人：SmithKline Beecham p.l.c.

  公开号：US20040010031A1

  公开（公告）日：2004-01-15

  A method for the treatment of conditions associated with a need for inhibition of GSK-3, such as diabetes, dementias such as Alzheimer's disease and manic depression which method comprises the administration of a pharmaceutically effective, non-toxic amount of a compound of formula (I): 1 or a pharmaceutically acceptable derivative thereof, wherein: R is hydrogen, alkyl, aryl, or aralkyl; R 1 is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl; R 2 is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl; R 3 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkoxyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or aralkyl wherein the aryl moiety is substituted or unsubstituted; or, R 1 and R 3 together with the nitrogen to which they are attached form a single or fused, optionally substituted, saturated or unsaturated heterocylic ring; to a human or non-human mammal in need thereof, and compounds of formula I.

  一种用于治疗与需要抑制GSK-3相关的疾病的方法，例如糖尿病、阿尔茨海默病和躁郁症，该方法包括向需要的人类或非人类哺乳动物投予化学药效、无毒量的化合物(I)的药物，其中：R为氢、烷基、芳基或芳基烷基；R1为氢、烷基、芳基烷基、羟基烷基或烷氧基烷基；R2为取代或未取代的芳基或取代或未取代的杂环烷基；R3为氢、取代或未取代的烷基、环烷基、烷氧基烷基、取代或未取代的芳基、取代或未取代的杂环烷基或芳基烷基，其中芳基部分为取代或未取代；或者，R1和R3与它们连接的氮一起形成单个或融合的、可选择取代的饱和或不饱和杂环环；以及化合物I的药物可接受衍生物。
• PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1119548A1

  公开（公告）日：2001-08-01
• 3-(3-CHLORO-4-HYDROXYPHENYLAMINO)-4-(2-NITROPHENYL)-1H-PYRROLE-2,5-DIONE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITOR (GSK-3)
  申请人：SmithKline Beecham plc

  公开号：EP1119548B1

  公开（公告）日：2004-12-08
• US6719520B2
  申请人：——

  公开号：US6719520B2

  公开（公告）日：2004-04-13
• [EN] NOVEL METHOD AND COMPOUNDS<br/>[FR] PROCEDE ET COMPOSES
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2000021927A2

  公开（公告）日：2000-04-20

  A method for the treatment of conditions associated with a need for inhibition of GSK-3, such as diabetes, dementias such as Alzheimer's disease and manic depression which method comprises the administration of a pharmaceutically effective, non-toxic amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein: R is hydrogen, alkyl, aryl, or aralkyl; R1 is hydrogen, alkyl, aralkyl, hydroxyalkyl or alkoxyalkyl; R2 is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclyl; R3 is hydrogen, substituted or unsubstituted alkyl, cycloalkyl, alkoxyalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or aralkyl wherein the aryl moiety is substituted or unsubstituted; or, R?1 and R3¿ together with the nitrogen to which they are attached form a single or fused, optionally substituted, saturated or unsaturated heterocylic ring; to a human or non-human mammal in need thereof.